Status:
RECRUITING
IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study
Lead Sponsor:
The Third Xiangya Hospital of Central South University
Conditions:
Crohn's Disease
Upadacitinib
Eligibility:
All Genders
18-80 years
Brief Summary
Crohn's disease (CD) is a chronic nonspecific inflammatory disease of the intestinal tract whose etiology is not yet fully understood, and can present with serious complications such as intestinal obs...
Detailed Description
Crohn's disease (CD) is a chronic nonspecific inflammatory disease of the intestinal tract whose etiology is not yet fully understood, and can present with serious complications such as intestinal obs...
Eligibility Criteria
Inclusion
- Age ≥ 18 years and ≤ 80 years;
- Patients with newly diagnosed or relapsed moderate to severe Crohn's disease
- Upadacitinib therapy is proposed to be applied within 1 month after baseline endoscopy and intestinal ultrasound,;
- No history of abdominal surgery;
- Clearly understand, voluntarily participate in the study, and sign an informed consent form.
Exclusion
- Contraindications to upadacitinib: allergy, active tuberculosis or other active infections, moderate-to-severe heart failure (NYHA grade III/ IV), demyelinating lesions of the nervous system, live vaccination within the last 3 months, pregnancy and lactation;
- Patients with a history of extensive colectomy or recent proposed colectomy, history of colonic mucosal dysplasia;
- Hypersensitivity to the components of SonoVue contrast media.
Key Trial Info
Start Date :
January 16 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06573944
Start Date
January 16 2024
End Date
September 30 2025
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Third Xiangya Hospital of Central South University
Hunan, Hunan, China, 410000